Zeng Yue, Pu Xing-Xiang, He Feng-Jiao, Hu Chun-Hong, Zhu Hong, Huang Yan, Peng Yu-Rong, Zou Ji-An, Liu Jun-Qi, Shi Sheng-Hao, Liu Yue-Fei, Ma Fang, Deng Chao, Qiu Zhen-Hua, Li Yan-Long, Zhang Ying-Zhe, Huang Kun, Liu Xian-Ling, Wu Fang
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China.
iScience. 2024 Jun 8;27(7):110219. doi: 10.1016/j.isci.2024.110219. eCollection 2024 Jul 19.
The resected pⅢA-N2 non-small-cell lung cancer (NSCLC) patients who could benefit from postoperative radiotherapy (PORT) are not well-defined. The study explored the role of PORT on EGFR mutant and wild-type NSCLC patients. We retrospectively searched for resected pIIIA-N2 lung adenocarcinoma patients who underwent EGFR mutation testing. 80 patients with EGFR wild-type and 85 patients with EGFR mutation were included. 62 patients received PORT. In overall population, the median disease-free survival (DFS) was improved in PORT arm compared to non-PORT arm (22.9 vs. 16.1 months; = 0.036), along with higher 2-year locoregional recurrence-free survival (LRFS) rate (88.3% vs. 69.3%; = 0.004). In EGFR wild-type patients, PORT was associated with a longer median DFS (23.3 vs. 17.2 months; = 0.044), and a higher 2-year LRFS rate (86.8% vs. 61.9%; = 0.012). In EGFR mutant patients, PORT was not significantly correlated with improved survival outcomes. EGFR wild-type may a biomarker to identify the cohort that benefits from PORT.
可从术后放疗（PORT）中获益的ⅢA-N2期非小细胞肺癌（NSCLC）患者尚未明确界定。本研究探讨了PORT对表皮生长因子受体（EGFR）突变型和野生型NSCLC患者的作用。我们回顾性检索了接受EGFR突变检测的ⅢA-N2期肺腺癌患者。纳入了80例EGFR野生型患者和85例EGFR突变型患者。62例患者接受了PORT。在总体人群中，PORT组的无病生存期（DFS）中位数较非PORT组有所改善（22.9个月对16.1个月；P = 0.036），同时2年局部区域无复发生存率（LRFS）更高（88.3%对69.3%；P = 0.004）。在EGFR野生型患者中，PORT与更长的DFS中位数相关（23.3个月对17.2个月；P = 0.044），以及更高的2年LRFS率（86.8%对61.9%；P = 0.012）。在EGFR突变型患者中，PORT与生存结局改善无显著相关性。EGFR野生型可能是识别能从PORT中获益人群的生物标志物。
